Phase 3 Completed N=130 Randomized Double-blind Treatment

Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

Hypertension

Source: ClinicalTrials.gov NCT00857285 ↗

Enrolled (actual)

130

Serious AEs

—

Results posted

Jul 2009

Primary outcomePrimary: Mean Change of Sitting dBP From Baseline to Week 12 — -14.80; -11.60 mmHg

Summary

The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Change of Sitting dBP From Baseline to Week 12	-14.80; -11.60	—

Eligibility Criteria

Inclusion Criteria

Diastolic BP 95 mm Hg - 114 mm Hg inclusive
No participation in any clinical trial for the last 3 months

Exclusion Criteria

Secondary hypertension
Malignant hypertension
Severe arterial hypertension
Significant cardiovascular disease
History or clinical evidence of cerebrovascular, gastrointestinal, hematological, hepatic disease, myocardial infarction, or severe liver disorder
Clinical evidence of renal disease, poorly controlled diabetes, known malabsorption syndromes, psychiatric/emotional problems

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00857285). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.